HomeAI · summaries
Storia in 6 fonti
Novartis pelacarsen Lp(a) trial fails, raising doubts for Amgen, Lilly
Pelacarsen lowered Lp(a) levels in more than 8,000 patients but did not reduce the risk of heart attacks, strokes, or cardiovascular death
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
Novartis' Phase 3 cardiovascular study miss raises the stakes for Amgen, Lilly
Novartis' pelacarsen fails Lp(a)HORIZON, the third major CV outcomes trial miss in two months, as Amgen, Lilly and others push ahead.
- ·
healio.com
‘Not the results we hoped for’: Lp(a)-lowering drug pelacarsen fails to reduce CV events
The Lp(a)HORIZON trial of pelacarsen, the first cardiovascular outcomes trial for an agent designed to lower lipoprotein(a), failed to achieve its primary outcome, Novartis…
